Singapore markets closed

  • Straits Times Index

    3,192.17
    -17.55 (-0.55%)
     

  • S&P 500

    4,163.26
    -22.21 (-0.53%)
     

  • Dow

    34,077.63
    -123.04 (-0.36%)
     

  • Nasdaq

    13,914.77
    -137.58 (-0.98%)
     

  • BTC-USD

    55,828.72
    -1,528.58 (-2.67%)
     

  • CMC Crypto 200

    1,260.15
    -38.80 (-2.99%)
     

  • FTSE 100

    6,915.11
    -84.97 (-1.21%)
     

  • Gold

    1,767.20
    -3.40 (-0.19%)
     

  • Crude Oil

    63.64
    +0.26 (+0.41%)
     

  • 10-Yr Bond

    1.6050
    +0.0040 (+0.25%)
     

  • Nikkei

    29,100.38
    -584.99 (-1.97%)
     

  • Hang Seng

    29,135.73
    +29.58 (+0.10%)
     

  • FTSE Bursa Malaysia

    1,607.57
    +7.28 (+0.45%)
     

  • Jakarta Composite Index

    6,038.32
    -14.22 (-0.23%)
     

  • PSE Index

    6,500.42
    +40.66 (+0.63%)
     
EXCLUSIVE:

DBS, OCBC among potential bidders for Citi's Asia consumer business - sources

Pakistan's inflation eases as COVID-19 hammers economy

By Asif Shahzad
·2-min read
FILE PHOTO: Outbreak of the coronavirus disease (COVID-19), in Karachi

By Asif Shahzad

ISLAMABAD (Reuters) - Pakistan's consumer price inflation eased to 9.5% in April, its statistics office said on Friday, extending a months-long decline as the economy tanks due to the coronavirus crisis despite three interest rate cuts.

The South Asian nation is struggling to keep its economy afloat as the reported number of infections from COVID-19, the highly contagious respiratory disease caused by the novel coronavirus, has risen to 16,817, with 385 deaths.

Consumer price inflation was 10.24% in March after having risen in January to 14.56%, its highest in over a decade, severely squeezing household budgets.

The central bank kept interest rates unchanged at 13.25% in January but, once the coronavirus began battering business and household finances, it slashed rates three times in recent weeks to 9% to help cushion the blow.

Pakistan now faces a balance of payment crisis as the economy heads towards a major recession with a 1.5 percent contraction forecast in the current financial year ending in June, compared with a pre-COVID-19 forecast of nearly 3% growth, according to the finance ministry and central bank.

Growth is projected to recover to about 2% in the 2021/22 fiscal year.

A steep drop in oil prices, which comprise most of Pakistan's import bill, has been welcome, allowing pump prices for petrol and diesel to be cut by 27% and 35% respectively since February, with the biggest cut coming on Thursday.

But critics say the government has not passed on the full advantage of the oil price fall to the public, instead raising taxes on petrol and diesel by up to 300%.

With the current account deficit mounting and foreign reserves shrivelling, businesses and industries that were shut to contain the spread of the coronavirus have been allowed to start reopening.

Pakistan agreed a $6 billion bailout from the International Monetary Fund last year and secured another $1.386 billion in rapid financing from the IMF at zero interest last month.

Islamabad is hoping for more bailout packages from the World Bank and other development partners as it plans to file for debt relief from G20 countries and bilateral partners, mainly longtime ally China.

(Writing by Asif Shahzad; Editing by Mark Heinrich)

Latest stories

  • $17 Billion E-Cigarette Market - Global Industry Trends, Share, Size, Growth, Opportunity and Forecast to 2026 - ResearchAndMarkets.com

    The "E-Cigarette Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

  • Heinen’s and Logile Celebrate Their Five Years of Collaboration

    Heinen's and Logile celebrate five years of collaboration as Heinen's improves employee scheduling effectiveness and store performance.

  • Marijuana Company of America Inc.’s CEO, Jesus Quintero, Answers Shareholder Questions and Provides Operational Update in New Interview

    AUSTIN, Texas, April 20, 2021 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (“SCV”) today announced the availability of a new interview with the Jesus Quintero, CEO of Marijuana Company of America Inc. ("MCOA" or the "Company") (OTC: MCOA), an innovative hemp corporation. Quintero answers shareholder questions that were submitted on the MCOA social media sites. Topics covered on the call included how MCOA will profit from efforts led by Cannabis Global, Inc. (OTC: CBGL) and Eco Innovation Group, Inc. (OTC: ECOX), several topics related to MCOA’s market value, where MCOA is at regarding a potential up-list to a higher exchange, what are plans for getting products into new states/countries as legalization continues to grow, and much more. While answering investor questions, Quintero tells Smith, “Our 2020 sales revenue was impacted by the global pandemic, but in 2021 we have shifted to our new eCommerce platform. This transition involved the rebranding of our products, utilizing our social media platforms to reach new markets, as well as introducing some new intangibles that are not being used by any of our competitors.” Regarding the work being done with ECOX and CBGL, Quintero says, “From the shareholder perspective you have to look beyond just the share exchange. In reality there is so much more to these strategic relationships. CBGL has several high-tech products, formulated beverages and innovations that MCOA can leverage and assist with along with numerous patents and extensive R&D. CBGL also has a controlling 56.5% interest in Natural Plant Extracts of California, a cannabis manufacturing and distribution plant in Lynwood, CA, that MCOA invested in two years ago. In terms of ECOX, they are a strong partner working with inventors and new inventions mostly surrounding green technology like their work with specialized supercritical extraction technology. We are three very impactful businesses that are made that much stronger by the work we will do together.” The full interview can be heard at: https://www.smallcapvoice.com/april-interview-marijuana-company-of-america-mcoa/. About Marijuana Company of America, Inc. MCOA is an emerging industry leader with focus in product development and sales & marketing with its proprietary botanical ingredients legal hemp-based cannabidiol ("CBD") quality products under the brand name "hempSMART™". The Company's premium quality products are double lab tested for purity and potency and sold to wholesalers, distributors, via online e commerce consumer platform, and a proven network affiliate marketing program. The Company recently announced plans for international sales, production, and marketing expansion. For more information, please visit: https://www.marijuanacompanyofamerica.com/ About SmallCapVoice.com SmallCapVoice.com, Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies, small cap and micro-cap stocks build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, podcasts, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTCMarkets. To learn more about SmallCapVoice.com and its services, please visit https://www.smallcapvoice.com/small-cap-stock-otc-investor-relations-financial-public-relations/. Socialize with SmallCapVoice and their clients at Facebook: https://www.facebook.com/SmallCapVoice/ Twitter: https://twitter.com/smallcapvoice Instagram: https://www.instagram.com/smallcapvoice/ Forward-Looking Information This news release contains "forward-looking statements" which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as "anticipate", "seek", intend", "believe", "estimate", "expect", "project", "plan", or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov. MCOA Contact:Tel: 888-777-4362Email: info@mcoainvestments.com SmallCapVoice.com Contact:Stuart T. Smith512-267-2430Info@SmallCapVoice.com Source: SmallCapVoice.com

  • Billie Eilish was spotted wearing this $7 mask that celebs and shoppers are obsessed with

    "They are like getting comfy new underwear," joked one reviewer.

  • Affinivax Appoints Stuart Chaffee, PhD, as Chief Business Officer

    Affinivax Appoints Stuart Chaffee, PhD, as Chief Business Officer

  • National Human Services Assembly Names Victor Valentine New Executive Director to Lead Expanded Strategic Direction

    Continued engagement of the human service sector to prioritize equityWASHINGTON, April 20, 2021 (GLOBE NEWSWIRE) -- The National Human Services Assembly (National Assembly) has selected Victor Valentine as executive director. He will oversee the expansion of National Assembly’s strategic direction enhancing the sector's positive impact on American communities. As a result of Mr. Valentine’s 20 years of experience in the areas of board and executive leadership development, strategic and operational planning, professional coaching and philanthropy, he will be instrumental to leading new and ongoing initiatives. This includes increasing the number of diverse leaders within the sector, convening human service leaders around timely issues, lifting voices of those working on youth justice and equity issues, building on lessons learned from the National Reframing Initiative, and serving as a collective voice in public policy and reform. The National Assembly will also continue an ongoing equity partnership with the National Alliance for Hispanic Health, an organization with a proud 47-year history of delivering front-line health and human services annually to over 15 million in underserved communities. “We are very excited to welcome Victor on board as our new Executive Director,” said Jeff Fleischer, Chair of the National Assembly Board of Directors and CEO of Youth Advocate Programs, Inc. “Victor brings a career of building trusting relationships with nonprofit human service leaders, advocates, and the philanthropic community. He has been the ’go to’ person for many leaders regarding race, equity, and inclusion work.” Before joining the National Assembly, Mr. Valentine served as founder and CEO of Nfrastruct, LLC, a nonprofit capacity-building consultancy. His past professional experience includes leadership positions with the Maryland Philanthropy Network, the New York City Urban League, the United Way of New York City, the Baltimore Mayor’s Office of Employment Development, and the Maryland General Assembly. “The National Human Services Assembly is uniquely positioned to serve as both convener and leader in the conversations around race, ethnicity, and equity. Doing so is a natural extension of the phenomenal history the members of the National Assembly have in building communities through comprehensive services, and as employers and contributors to our communities,” Mr. Valentine said. “I look forward to working with the board and members, its supporters, and new allies to facilitate the much-needed change our communities so deserve.” A graduate of the University of Maryland at College Park and Wilmington University where he earned his BA in Political Science and MA in Public Administration respectively, Mr. Valentine is also an alumnus of the American Express Leadership Academy for Nonprofit Leaders. National Assembly members are some of the nation’s most engaged human services organizations that collectively strengthen the sector and support a nation where everyone can reach their full potential. Mr. Valentine will also serve as executive director of National Assembly Business Services, Inc. (NABS), a for-profit subsidiary of National Assembly. NABS operates PurchasingPoint®, a discount group purchasing program that leverages $45 billion in annual purchasing and since 2004 has saved nonprofits an estimated $198 million for mission-related activities. About the National Human Services AssemblyNational Human Services Assembly (National Assembly) envisions a connected and engaged nation that promotes and supports human services so all people can reach their potential and contribute to vibrant, thriving communities. The National Assembly is a leading voice in strengthening the human service sector. It seeks to leverage its collective resources and influence to promote collaboration, diversity in leadership, and equitable practices among engaged organizations to advance the collective power, knowledge, strategy, and systems that build well-being within individuals and our communities. It is also committed to driving change in the human service sector through its public policy and REDI (Race, Equity, Diversity & Inclusion) work, among other initiatives. MEDIA CONTACT:Michelle Stewart202-347-2080 ext. 23mstewart@nassembly.org

  • Entera Announces Ron Mayron, a Global Pharma Leader, Joins its Board of Directors

    BOSTON and JERUSALEM, April 20, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that Ron Mayron has joined its Board of Directors. Mr. Mayron is taking the seat of Zeev Bronfeld, a Founder of Entera, who served on its Board since 2010, and was Chairman from 2014 to 2016. Mr. Mayron is global healthcare specialist who serves on the boards of numerous public and privately held pharma and medical device companies in Israel, including DNA BioMedical Solutions, Innocan Pharma, and IceCure Medical. His prior executive experience includes several leadership positions culminating in CEO of Teva Israel & Africa and CEO of S.L.E. His expertise within healthcare includes M&A, integration and implementation, global business development, global operations, and supply chain management. He earned a B.Sc. from Ben-Gurion University, an MBA from the University of Tel Aviv, and attended several programs at Insead University Fontainebleu, France and the Massachusetts Institute of Technology, Boston. Mr. Mayron served as an Officer in the Israeli army achieving the rank of Major. Jerry Lieberman, Entera’s Chairman commented, “We welcome Ron to the Board as we advance our pipeline of oral drug candidates for biologics and active ingredients that were previously only administrated through injection. Ron’s deep knowledge in the management and logistics of commercialized pharma products at Teva, as well as his vast experience serving on the boards of over a dozen private and publicly traded healthcare companies are assets to Entera.” “On behalf of the entire Board, I extend gratitude to Zeev for his insight as a Founder of Entera, his leadership as a Board member, and his twelve years of service to the Company. His contributions have helped Entera become a NASDAQ listed company and a global leader in the oral delivery of proteins. We wish him well,” Mr. Lieberman concluded. About Entera Bio Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company’s proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company’s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com. Forward Looking Statements Various statements in this release are “forward-looking statements” under the securities laws. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Important factors that could cause actual results to differ materially from those reflected in Entera’s forward-looking statements include, among others: changes in our interpretation of the complete3-month biomarker data from the ongoing Phase 2 clinical trial of EB613, the timing of data readouts from the ongoing Phase 2 clinical trial of EB613, the full results of the Phase 2 clinical trial of EB613, which is still ongoing and our analysis of those full results, the FDA’s interpretation and review of our results from and analysis of our Phase 2 trial of EB613, unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; a possible suspension of the Phase 2 clinical trial of EB613 for clinical or data-related reasons; the impact of COVID-19 on Entera’s business operations including the ability to collect the necessary data from the Phase 2 trial of EB613; the potential disruption and delay of manufacturing supply chains, loss of available workforce resources, either by Entera or its collaboration and laboratory partners, due to travel restrictions, lay-offs or forced closures or repurposing of hospital facilities; impacts to research and development or clinical activities that Entera is contractually obligated to provide, such as those pursuant to Entera’s agreement with Amgen; overall regulatory timelines, if the FDA or other authorities are closed for prolonged periods, choose to allocate resources to review of COVID-19 related drugs or believe that the amount of Phase 2 clinical data collected are insufficient to initiate a Phase 3 trial, or a meaningful deterioration of the current political, legal and regulatory situation in Israel or the United States; the availability, quality and timing of the data from the Phase 2 clinical trial of EB613 in osteoporosis patients; the ability to find a dose that demonstrates the comparability of EB613 to FORTEO in the ongoing Phase 2 clinical trial of EB613; the size and growth of the potential market for EB613 and Entera’s other product candidates including any possible expansion of the market if an orally delivered option is available in addition to an injectable formulation; the scope, progress and costs of developing Entera’s product candidates including EB612 and GLP-2; Entera’s reliance on third parties to conduct its clinical trials; Entera’s expectations regarding licensing, business transactions and strategic collaborations; Entera’s operation as a development stage company with limited operating history; Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s expectations regarding its expenses, revenue, cash resources, liquidity and financial condition; Entera’s ability to raise additional capital; Entera’s interpretation of FDA feedback and guidance and how such guidance may impact its clinical development plans; Entera’s ability to obtain and maintain regulatory approval for any of its product candidates; Entera’s ability to comply with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera’s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the “Special Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s annual and current filings which are on file with the SEC and available free of charge on the SEC’s website at http://www.sec.gov. Additional factors may be set forth in those sections of Entera’s Annual Report on Form 20-F for the year ended December 31, 2020, filed with the SEC in the first quarter of 2021. In addition to the risks described above and in Entera’s annual report on Form 20-F and current reports on Form 6-K and other filings with the SEC, other unknown or unpredictable factors also could affect Entera’s results. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved. All written and verbal forward-looking statements attributable to Entera or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Entera undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Contact: Spiros Jamas, CEOTel: +001 617-362-3579spiros@enterabio.com

  • Schneider Electric Solar Opens Online Store

    Schneider Electric Solar has announced the Schneider Electric Solar Store, an e-commerce store where customers can purchase Schneider Electric’s solar products. Schneider Electric Solar is looking to enhance the experience of their customers with the convenience of online shopping.

  • Biotech Veterans Troy Cox, Susannah Gray and Karen McGinnis Join Biosplice Therapeutics Board of Directors

    SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of three independent directors to its board. New directors comprise Troy Cox, former CEO of Foundation Medicine, Susannah Gray, former EVP and CFO of Royalty Pharma Management, and Karen McGinnis, former VP and CAO of Illumina. “We are honored to have this caliber of experience and leadership join our new board at Biosplice,” said Osman Kibar, PhD, Founder and Executive Chairman of Biosplice. “Ms. Gray, Ms. McGinnis, and Mr. Cox bring invaluable insight to our company as we continue the buildout of our alternative splicing platform and navigate the final stages of clinical development for our lead osteoarthritis drug candidate, lorecivivint, and continue to develop our promising oncology and neurology pipelines.” Troy Cox led Foundation Medicine (NASDAQ: FMI), as President and Chief Executive Officer, through the acquisition by Roche for $5.3 billion in 2018. Prior to Foundation Medicine, he served as Senior Vice President and Officer at Genentech, where he led US BioOncology for a period of unprecedented growth to over $12 billion while accountable to help steer the Roche Genentech R&D portfolio. Before Genentech, Mr. Cox held executive and senior roles, including President UCB BioPharmaceuticals, Senior Vice President Sanofi-Aventis and diverse foundational roles at Schering-Plough. He also currently serves as a director of Zymeworks, Inc. (NYSE: ZYME), Sophia Genetics, LetsGetChecked, CM Life Sciences II (NASDAQ: CMIIU) and MassBio. Susannah Gray brings more than 30 years of biopharmaceutical experience, specifically in corporate finance and capital markets roles, most recently serving as Executive Vice President, Finance & Strategy of Royalty Pharma Management, LLC. Ms. Gray also spent 14 years as Executive Vice President and Chief Financial Officer of Royalty Pharma before retiring in 2019. Prior to joining Royalty Pharma, she had a 14-year career in banking, working in various capacities within high yield and structured finance departments of Chase Securities, Merrill Lynch and CIBC World Markets. Ms. Gray also serves as a director of Maravai LifeSciences (NASDAQ: MRVI) and 4D Molecular Therapeutics (NASDAQ: FDMT). Karen McGinnis has over 20 years of experience in executive operational and finance roles at international public companies. She most recently served as Vice President & Chief Accounting Officer of Illumina, Inc. (NASDAQ: ILMN), a leader in sequencing- and array-based solutions for genetic and genomic analysis. Earlier in her career, Ms. McGinnis served as Director, President and Chief Executive Officer, and previously Chief Financial Officer, of Mad Catz Interactive, Inc. (OTC: MCZAF), a global provider of innovative interactive entertainment products. Prior to joining Mad Catz, Ms. McGinnis served as Chief Accounting Officer of Cymer, Inc., a leading supplier to the semiconductor industry and, previously, Chief Accounting Officer for Insight Enterprises, Inc. Ms. McGinnis also currently serves as a director of Alphatec Holdings, Inc. (NASDAQ: ATEC) and AbSci, Inc. Learn more about Biosplice’s Board of Directors at https://www.biosplice.com/board-of-directors About BiospliceBiosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing. Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. Biosplice’s target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular “command and control” center. Biosplice’s drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer’s disease to other degenerative conditions. Learn more at https://www.biosplice.com Corporate Contact: Erich HorsleyBiosplice Therapeutics, Inc.erich.horsley@biosplice.com858-365-0200

  • $3.5M+ USD Raised In 2 Hours? This Crypto Exchange Converts Influencer Reputation Into Bitcoin...

    Meet the influencer stock market.Dubai, UAE, April 20, 2021 (GLOBE NEWSWIRE) -- (via Blockchain Wire) WithdrawBitClout, the first-ever exchange for users to realize their wealth on the BitClout platform. Its fast-growing market cap reflects how transformative this project is for BitClout. View and download BitClout photo here. They’ve recently just reached #7 on the BitClout leaderboards as they’re now worth $4.5 million. This makes them the only account on BitClout’s top 10 list that doesn’t have a blue-tick verification. What is BitClout? It’s the influencer stock market — a decentralized Twitter where user reputation is pegged to a dollar amount. It allows users to have their own unique coin that can grow in value when people buy it. Celebrities such as Jake Paul, Paul Pogba, and Grant Cardone already have their coin valued at thousands — higher than most cryptocurrencies. But without an exchange, $10,000 in BitClout is the equivalent to $10,000 typed on a calculator. It means nothing. This is why WithdrawBitClout’s market cap is growing in millions by the minute. It’s the final piece of the BitClout puzzle. More About WithdrawBitClout It was founded by Marion Awfal, an established BitClout user who’s worth over $11,000 on the platform. His team consists of active Bitclout users who are trusted also. Transparency is a top priority on WithdrawBitClout so everyone has a consistently safe and decentralized experience. What’s even better is there incredibly low fees — 2% from buyers and sellers. Many exchanges bait users into their platform through low trading fees but exploit them with deposit and withdrawal fees. WithdrawBitClout isn’t one of these exchanges. Its peer-to-peer nature makes it impossible for them to take advantage of their users. Ways To Earn on WithdrawBitClout Dividends: WithdrawBitclout shares 50% of their earnings with those who invest in their creator coin.As volume on the exchange increases, the 2% return from fees becomes bigger.Small investors are rewarded too — 10% of dividends are distributed evenly to all coin holders with over 0.001 of WithdrawBitClout creator coins. Payouts are daily. Arbitrage: A crypto’s price is determined by a market and markets never have the exact same price for a cryptocurrency.WithdrawBitClout’s price won’t be the same as the price listed on BitClout.You’ll have opportunities to buy BitClout at desired prices and sell them high. WithdrawBitclout is Just The Base Layer The team is already planning projects to be built on top of it. They plan to revolutionize how businesses are built. This will inevitably add value to the BitClout ecosystem and create a growing demand that forces the crypto world to respect its presence. Possibly, one of BitClout’s own initial backers (Coinbase) could eventually onboard it and turn it mainstream overnight. This all starts with WithdrawBitclout. It’s the tool that makes the value of BitClout and its users meaningful. Once people realize their social media activity can be equated to dollars through BitClout and then turned into Bitcoin through WithdrawBitclout, it will be a game-changer. WithdrawBitClout adds the Bit(Bitcoin) to the Clout. To stay informed with the latest, as well as updates from the team, follow these communication channels listed here: Website: https://withdrawbitclout.com BitClout: https://bitclout.com/u/withdrawbitclout Founder: https://bitclout.com/u/marionawfal CONTACT: Ross Davis Global Crypto Press team@globalcryptopress.com https://withdrawbitclout.com

  • Global Electric Enclosure Market (2020 to 2026) - Featuring ABB, Eaton and Emerson Electric Among Others - ResearchAndMarkets.com

    The "Global Electric Enclosure Market 2020-2026" report has been added to ResearchAndMarkets.com's offering.

  • Tech Startup New Era ADR Aims to Disrupt Traditional Litigation and Dispute Resolution with New Technology Platform

    Tech startup New Era ADR introduces the first fully virtual platform that resolves business disputes in under 100 days & saves 90% in time & expenses.

  • Global Ultrasound Image Analysis Software Market to Reach $1.3 Billion by 2027

    Abstract: - Global Ultrasound Image Analysis Software Market to Reach $1. 3 Billion by 2027. - Amid the COVID-19 crisis, the global market for Ultrasound Image Analysis Software estimated at US$797.New York, April 20, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Ultrasound Image Analysis Software Industry" - https://www.reportlinker.com/p06033186/?utm_source=GNW 8 Million in the year 2020, is projected to reach a revised size of US$1.3 Billion by 2027, growing at aCAGR of 7.6% over the period 2020-2027. Integrated, one of the segments analyzed in the report, is projected to record 8% CAGR and reach US$800.3 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Standalone segment is readjusted to a revised 7.1% CAGR for the next 7-year period. - The U.S. Market is Estimated at $215.6 Million, While China is Forecast to Grow at 11.6% CAGR - The Ultrasound Image Analysis Software market in the U.S. is estimated at US$215.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$300.5 Million by the year 2027 trailing a CAGR of 11.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.1% and 6.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR. - Select Competitors (Total 36 Featured) - AGFA HealthcareAquilabCarestream Health, Inc.Esaote S.p.AGE HealthcareImage AnalysisINFINITT Healthcare Co, Ltd.Merge Healthcare, Inc.MIM Software Inc.Mirada Medical LimitedPhilips HealthcareScienceSoft USA CorporationSiemens HealthineersToshiba Medical Systems CorporationXinapse Systems Ltd. Read the full report: https://www.reportlinker.com/p06033186/?utm_source=GNW I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Ultrasound Image Analysis Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 2: World Historic Review for Ultrasound Image Analysis Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 3: World 15-Year Perspective for Ultrasound Image Analysis Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Integrated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 5: World Historic Review for Integrated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 6: World 15-Year Perspective for Integrated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Standalone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 8: World Historic Review for Standalone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 9: World 15-Year Perspective for Standalone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 11: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 12: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for Orthopedic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 14: World Historic Review for Orthopedic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 15: World 15-Year Perspective for Orthopedic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for Dental by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 17: World Historic Review for Dental by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 18: World 15-Year Perspective for Dental by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 19: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 20: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 21: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 22: World Current & Future Analysis for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 23: World Historic Review for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 24: World 15-Year Perspective for Cardiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 25: World Current & Future Analysis for Obstetrics & Gynecology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 26: World Historic Review for Obstetrics & Gynecology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 27: World 15-Year Perspective for Obstetrics & Gynecology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 28: World Current & Future Analysis for Radiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 29: World Historic Review for Radiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 30: World 15-Year Perspective for Radiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 31: World Current & Future Analysis for Nephrology & Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 32: World Historic Review for Nephrology & Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 33: World 15-Year Perspective for Nephrology & Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 34: World Current & Future Analysis for 3D & 4D by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 35: World Historic Review for 3D & 4D by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 36: World 15-Year Perspective for 3D & 4D by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 37: World Current & Future Analysis for 2D by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 38: World Historic Review for 2D by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 39: World 15-Year Perspective for 2D by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 40: World Current & Future Analysis for Doppler Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 41: World Historic Review for Doppler Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 42: World 15-Year Perspective for Doppler Imaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Table 43: USA Current & Future Analysis for Ultrasound Image Analysis Software by Type - Integrated and Standalone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 44: USA Historic Review for Ultrasound Image Analysis Software by Type - Integrated and Standalone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 45: USA 15-Year Perspective for Ultrasound Image Analysis Software by Type - Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 Table 46: USA Current & Future Analysis for Ultrasound Image Analysis Software by Application - Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 47: USA Historic Review for Ultrasound Image Analysis Software by Application - Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 48: USA 15-Year Perspective for Ultrasound Image Analysis Software by Application - Percentage Breakdown of Value Sales for Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology for the Years 2012, 2020 & 2027 Table 49: USA Current & Future Analysis for Ultrasound Image Analysis Software by Segment - 3D & 4D, 2D and Doppler Imaging - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 50: USA Historic Review for Ultrasound Image Analysis Software by Segment - 3D & 4D, 2D and Doppler Imaging Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 51: USA 15-Year Perspective for Ultrasound Image Analysis Software by Segment - Percentage Breakdown of Value Sales for 3D & 4D, 2D and Doppler Imaging for the Years 2012, 2020 & 2027 CANADA Table 52: Canada Current & Future Analysis for Ultrasound Image Analysis Software by Type - Integrated and Standalone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 53: Canada Historic Review for Ultrasound Image Analysis Software by Type - Integrated and Standalone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 54: Canada 15-Year Perspective for Ultrasound Image Analysis Software by Type - Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 Table 55: Canada Current & Future Analysis for Ultrasound Image Analysis Software by Application - Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 56: Canada Historic Review for Ultrasound Image Analysis Software by Application - Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 57: Canada 15-Year Perspective for Ultrasound Image Analysis Software by Application - Percentage Breakdown of Value Sales for Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology for the Years 2012, 2020 & 2027 Table 58: Canada Current & Future Analysis for Ultrasound Image Analysis Software by Segment - 3D & 4D, 2D and Doppler Imaging - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 59: Canada Historic Review for Ultrasound Image Analysis Software by Segment - 3D & 4D, 2D and Doppler Imaging Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 60: Canada 15-Year Perspective for Ultrasound Image Analysis Software by Segment - Percentage Breakdown of Value Sales for 3D & 4D, 2D and Doppler Imaging for the Years 2012, 2020 & 2027 JAPAN Table 61: Japan Current & Future Analysis for Ultrasound Image Analysis Software by Type - Integrated and Standalone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 62: Japan Historic Review for Ultrasound Image Analysis Software by Type - Integrated and Standalone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 63: Japan 15-Year Perspective for Ultrasound Image Analysis Software by Type - Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 Table 64: Japan Current & Future Analysis for Ultrasound Image Analysis Software by Application - Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 65: Japan Historic Review for Ultrasound Image Analysis Software by Application - Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 66: Japan 15-Year Perspective for Ultrasound Image Analysis Software by Application - Percentage Breakdown of Value Sales for Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology for the Years 2012, 2020 & 2027 Table 67: Japan Current & Future Analysis for Ultrasound Image Analysis Software by Segment - 3D & 4D, 2D and Doppler Imaging - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 68: Japan Historic Review for Ultrasound Image Analysis Software by Segment - 3D & 4D, 2D and Doppler Imaging Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 69: Japan 15-Year Perspective for Ultrasound Image Analysis Software by Segment - Percentage Breakdown of Value Sales for 3D & 4D, 2D and Doppler Imaging for the Years 2012, 2020 & 2027 CHINA Table 70: China Current & Future Analysis for Ultrasound Image Analysis Software by Type - Integrated and Standalone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 71: China Historic Review for Ultrasound Image Analysis Software by Type - Integrated and Standalone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 72: China 15-Year Perspective for Ultrasound Image Analysis Software by Type - Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 Table 73: China Current & Future Analysis for Ultrasound Image Analysis Software by Application - Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 74: China Historic Review for Ultrasound Image Analysis Software by Application - Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 75: China 15-Year Perspective for Ultrasound Image Analysis Software by Application - Percentage Breakdown of Value Sales for Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology for the Years 2012, 2020 & 2027 Table 76: China Current & Future Analysis for Ultrasound Image Analysis Software by Segment - 3D & 4D, 2D and Doppler Imaging - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 77: China Historic Review for Ultrasound Image Analysis Software by Segment - 3D & 4D, 2D and Doppler Imaging Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 78: China 15-Year Perspective for Ultrasound Image Analysis Software by Segment - Percentage Breakdown of Value Sales for 3D & 4D, 2D and Doppler Imaging for the Years 2012, 2020 & 2027 EUROPE Table 79: Europe Current & Future Analysis for Ultrasound Image Analysis Software by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 80: Europe Historic Review for Ultrasound Image Analysis Software by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 81: Europe 15-Year Perspective for Ultrasound Image Analysis Software by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 82: Europe Current & Future Analysis for Ultrasound Image Analysis Software by Type - Integrated and Standalone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 83: Europe Historic Review for Ultrasound Image Analysis Software by Type - Integrated and Standalone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 84: Europe 15-Year Perspective for Ultrasound Image Analysis Software by Type - Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 Table 85: Europe Current & Future Analysis for Ultrasound Image Analysis Software by Application - Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 86: Europe Historic Review for Ultrasound Image Analysis Software by Application - Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 87: Europe 15-Year Perspective for Ultrasound Image Analysis Software by Application - Percentage Breakdown of Value Sales for Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology for the Years 2012, 2020 & 2027 Table 88: Europe Current & Future Analysis for Ultrasound Image Analysis Software by Segment - 3D & 4D, 2D and Doppler Imaging - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 89: Europe Historic Review for Ultrasound Image Analysis Software by Segment - 3D & 4D, 2D and Doppler Imaging Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 90: Europe 15-Year Perspective for Ultrasound Image Analysis Software by Segment - Percentage Breakdown of Value Sales for 3D & 4D, 2D and Doppler Imaging for the Years 2012, 2020 & 2027 FRANCE Table 91: France Current & Future Analysis for Ultrasound Image Analysis Software by Type - Integrated and Standalone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 92: France Historic Review for Ultrasound Image Analysis Software by Type - Integrated and Standalone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 93: France 15-Year Perspective for Ultrasound Image Analysis Software by Type - Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 Table 94: France Current & Future Analysis for Ultrasound Image Analysis Software by Application - Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 95: France Historic Review for Ultrasound Image Analysis Software by Application - Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 96: France 15-Year Perspective for Ultrasound Image Analysis Software by Application - Percentage Breakdown of Value Sales for Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology for the Years 2012, 2020 & 2027 Table 97: France Current & Future Analysis for Ultrasound Image Analysis Software by Segment - 3D & 4D, 2D and Doppler Imaging - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 98: France Historic Review for Ultrasound Image Analysis Software by Segment - 3D & 4D, 2D and Doppler Imaging Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 99: France 15-Year Perspective for Ultrasound Image Analysis Software by Segment - Percentage Breakdown of Value Sales for 3D & 4D, 2D and Doppler Imaging for the Years 2012, 2020 & 2027 GERMANY Table 100: Germany Current & Future Analysis for Ultrasound Image Analysis Software by Type - Integrated and Standalone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 101: Germany Historic Review for Ultrasound Image Analysis Software by Type - Integrated and Standalone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 102: Germany 15-Year Perspective for Ultrasound Image Analysis Software by Type - Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 Table 103: Germany Current & Future Analysis for Ultrasound Image Analysis Software by Application - Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 104: Germany Historic Review for Ultrasound Image Analysis Software by Application - Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 105: Germany 15-Year Perspective for Ultrasound Image Analysis Software by Application - Percentage Breakdown of Value Sales for Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology for the Years 2012, 2020 & 2027 Table 106: Germany Current & Future Analysis for Ultrasound Image Analysis Software by Segment - 3D & 4D, 2D and Doppler Imaging - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 107: Germany Historic Review for Ultrasound Image Analysis Software by Segment - 3D & 4D, 2D and Doppler Imaging Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 108: Germany 15-Year Perspective for Ultrasound Image Analysis Software by Segment - Percentage Breakdown of Value Sales for 3D & 4D, 2D and Doppler Imaging for the Years 2012, 2020 & 2027 ITALY Table 109: Italy Current & Future Analysis for Ultrasound Image Analysis Software by Type - Integrated and Standalone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 110: Italy Historic Review for Ultrasound Image Analysis Software by Type - Integrated and Standalone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 111: Italy 15-Year Perspective for Ultrasound Image Analysis Software by Type - Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 Table 112: Italy Current & Future Analysis for Ultrasound Image Analysis Software by Application - Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 113: Italy Historic Review for Ultrasound Image Analysis Software by Application - Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 114: Italy 15-Year Perspective for Ultrasound Image Analysis Software by Application - Percentage Breakdown of Value Sales for Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology for the Years 2012, 2020 & 2027 Table 115: Italy Current & Future Analysis for Ultrasound Image Analysis Software by Segment - 3D & 4D, 2D and Doppler Imaging - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 116: Italy Historic Review for Ultrasound Image Analysis Software by Segment - 3D & 4D, 2D and Doppler Imaging Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 117: Italy 15-Year Perspective for Ultrasound Image Analysis Software by Segment - Percentage Breakdown of Value Sales for 3D & 4D, 2D and Doppler Imaging for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 118: UK Current & Future Analysis for Ultrasound Image Analysis Software by Type - Integrated and Standalone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 119: UK Historic Review for Ultrasound Image Analysis Software by Type - Integrated and Standalone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 120: UK 15-Year Perspective for Ultrasound Image Analysis Software by Type - Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 Table 121: UK Current & Future Analysis for Ultrasound Image Analysis Software by Application - Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 122: UK Historic Review for Ultrasound Image Analysis Software by Application - Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 123: UK 15-Year Perspective for Ultrasound Image Analysis Software by Application - Percentage Breakdown of Value Sales for Oncology, Orthopedic, Dental, Other Applications, Cardiology, Obstetrics & Gynecology, Radiology and Nephrology & Oncology for the Years 2012, 2020 & 2027 Table 124: UK Current & Future Analysis for Ultrasound Image Analysis Software by Segment - 3D & 4D, 2D and Doppler Imaging - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 125: UK Historic Review for Ultrasound Image Analysis Software by Segment - 3D & 4D, 2D and Doppler Imaging Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 126: UK 15-Year Perspective for Ultrasound Image Analysis Software by Segment - Percentage Breakdown of Value Sales for 3D & 4D, 2D and Doppler Imaging for the Years 2012, 2020 & 2027 SPAIN Table 127: Spain Current & Future Analysis for Ultrasound Image Analysis Software by Type - Integrated and Standalone - Please contact our Customer Support Center to get the complete Table of ContentsRead the full report: https://www.reportlinker.com/p06033186/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

  • Genius Sports Closes Business Combination with dMY Technology Group, Inc. II and Will Begin Trading on the New York Stock Exchange

    Genius Sports Group ("GSG") the official data, technology and commercial partner that powers the global ecosystem connecting sports, betting and media, announced today that it has completed its previously announced business combination (the "Business Combination") with dMY Technology Group, Inc. II ("dMY II"). The Business Combination was approved at a special meeting of dMY II’s stockholders held Friday, April 16.

  • Global Industrial Robot Market (2021 to 2025) - Growing Role of Artificial Intelligence Technology is Driving the Industry

    Dublin, April 20, 2021 (GLOBE NEWSWIRE) -- The "Global Industrial Robot Market: Size, Trends and Forecast (2021-2025 Edition)" report has been added to ResearchAndMarkets.com's offering. This report provides an in-depth analysis of the industrial robot market including detailed description of market sizing and growth. The report provides an analysis of the global industrial robot market by value, by volume and includes segment analysis and application analysis as well. The report also includes an in-depth analysis of the industrial robot market for the following regions: Asia-Pacific, Europe, Americas and ROW. Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global industrial robot market has also been forecasted for the period 2021-2025, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. The major players dominating the industrial robot market are Fanuc Corporation, ABB Group, KUKA Group and Yaskawa Electric Corporation. The four companies have been profiled in the report providing their business overview, financial overview and business strategies. Country Coverage Asia-PacificEuropeAmericasROW Industrial robots have been segmented on the basis of type, end-user and function. The types of industrial robots include articulated, Cartesian, cylindrical, selective compliant assembly robot arm (SCARA), parallel and others. On the basis of application, industrial robots have been divided into automotive, electrical/ electronics, metal and machinery, plastic and chemical products, food and others. Various functions performed by industrial robots include soldering and welding, material handling, assembling and disassembling, painting and dispensing, milling, cutting, processing, etc. The global industrial robot market has witnessed continuous growth in the past few years and is projected to grow even further during the forecast period (2021-2025). The market is expected to be driven by various growth enhancing factors such as growing electronics industry, declining industrial robot prices, high labor costs, etc. However, the market is not free from challenges that are hindering its growth. Some of the major challenges faced by the market are large upfront investment and safety issues. Key Topics Covered: 1. Executive Summary 2. Introduction2.1 Industrial Robots: An Overview2.1.1 Evolution of Industrial Robots2.1.2 Types of Industrial Robots2.2 Advantages and Disadvantages of Industrial Robots2.2.1 Advantages of Industrial Robots2.2.2 Disadvantages of Industrial Robots2.3 Industrial Robots Segmentation: An Overview2.3.1 Industrial Robots Segmentation by Type2.3.2 Industrial Robots Segmentation by Application2.3.3 Industrial Robots Segmentation by Function 3. Global Market Analysis3.1 Global Industrial Robot Market: An Analysis3.1.1 Global Industrial Robot Market by Value3.1.2 Global Industrial Robot Market Value by Region (Asia-Pacific, Europe, Americas and ROW)3.1.3 Global Industrial Robot Market by Volume3.1.4 Global Industrial Robot Market Volume by Application (Electrical/ Electronics, Automotive, Metal and Machinery, Plastic and Chemical Products, Food and Other Applications)3.1.5 Global Industrial Robot Market Volume by Region (Asia-Pacific, Europe and Americas)3.1.6 Global Industrial Robot Market Volume by Segments (Traditional Industrial Robots and Collaborative Industrial Robots)3.2 Global Industrial Robot Market: Segment Analysis3.2.1 Global Traditional Industrial Robot Market by Volume3.2.2 Global Collaborative Industrial Robot Market by Volume3.3 Global Industrial Robot Market: Application Analysis3.3.1 Global Automotive Industrial Robot Market by Volume3.3.2 Global Electrical/ Electronics Industrial Robot Market by Volume3.3.3 Global Metal and Machinery Industrial Robot Market by Volume3.3.4 Global Plastic and Chemical Products Industrial Robot Market by Volume3.3.5 Global Food Industrial Robot Market by Volume3.3.6 Global Other Applications Industrial Robot Market by Volume 4. Regional Market Analysis4.1 Asia-Pacific Industrial Robot Market: An Analysis4.1.1 Asia-Pacific Industrial Robot Market by Value4.1.2 Asia-Pacific Industrial Robot Market Value by Region (China and Asia-Pacific (excluding China))4.1.3 China Industrial Robot Market by Value4.1.4 China Industrial Robot Market Value by Product Type (Articulated, SCARA, Gantry, Cartesian, Collaborative, Parallel and Cylindrical)4.1.5 China Cylindrical Industrial Robot Market by Value4.1.6 China Parallel Industrial Robot Market by Value4.1.7 China Collaborative Industrial Robot Market by Value4.1.8 China Cartesian Industrial Robot Market by Value4.1.9 China Gantry Industrial Robot Market by Value4.1.10 China SCARA Industrial Robot Market by Value4.1.11 China Articulated Industrial Robot Market by Value4.1.12 Asia-Pacific (Excluding China) Industrial Robot Market by Value4.1.13 Asia-Pacific Industrial Robot Market by Volume4.1.14 Asia-Pacific Industrial Robot Market Volume by Region (China, Republic of Korea, Japan and Asia-Pacific (excluding China, Japan and Republic of Korea))4.1.15 China Industrial Robot Market by Volume4.1.16 Japan Industrial Robot Market by Volume4.1.17 Republic of Korea Industrial Robot Market by Volume4.1.18 Asia-Pacific (Excluding China, Japan and Republic of Korea) Industrial Robot Market by Volume4.2 Europe Industrial Robot Market: An Analysis4.2.1 Europe Industrial Robot Market by Value4.2.2 Europe Industrial Robot Market Value by Region (Italy and Europe (excluding Italy))4.2.3 Italy Industrial Robot Market by Value4.2.4 Italy Industrial Robot Market Value by Application (Automotive, Electrical/ Electronics, Metal/ Heavy machinery, Chemical, Rubber & Plastics, Food and Other Applications)4.2.5 Italy Industrial Robot Market Application by Value4.2.6 Europe (Excluding Italy) Industrial Robot Market by Value4.2.7 Europe Industrial Robot Market by Volume4.2.8 Europe Industrial Robot Market Volume by Region (Germany and Europe (excluding Germany))4.2.9 Germany Industrial Robot Market by Volume4.2.10 Europe (Excluding Germany) Industrial Robot Market by Volume4.3 Americas Industrial Robot Market: An Analysis4.3.1 Americas Industrial Robot Market by Value4.3.2 Americas Industrial Robot Market by Volume4.3.3 Americas Industrial Robot Market Volume by Region (North America and South America)4.3.4 North America Industrial Robot Market by Volume4.3.5 South America Industrial Robot Market by Volume4.4 ROW Industrial Robot Market: An Analysis4.4.1 ROW Industrial Robot Market by Value 5. Market Dynamics5.1 Growth Drivers5.1.1 Growing Electronics Industry5.1.2 Declining Industrial Robot Prices5.1.3 Growth of Automotive Industry5.1.4 High Labor Costs5.1.5 Rising Trend of Automation5.1.6 Growing Role of Artificial Intelligence Technology5.2 Challenges5.2.1 Large Upfront Investment5.2.2 Safety Issues5.3 Market Trends5.3.1 Use of Microelectromechanical Systems (MEMS)5.3.2 Cloud Robotics5.3.3 Rising Use of Collaborative Robots (Cobot) in Industries 6. Competitive Landscape6.1 Global Industrial Robot Market Players: Financial Comparison6.2 Global Industrial Robot Players by Market Share 7. Company Profiles7.1 Fanuc Corporation7.1.1 Business Overview7.1.2 Financial Overview7.1.3 Business Strategy7.2 ABB Group7.2.1 Business Overview7.2.2 Financial Overview7.2.3 Business Strategy7.3 KUKA Group7.3.1 Business Overview7.3.2 Financial Overview7.3.3 Business Strategy7.4 Yaskawa Electric Corporation7.4.1 Business Overview7.4.2 Financial Overview7.4.3 Business Strategy For more information about this report visit https://www.researchandmarkets.com/r/g42n0i CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

  • Cecil Ray Baker, Just-Eliminated 'American Idol' Contestant, Accused Of Hitting Ex-Girlfriend

    The country singer was arrested just days after the talent show voted him off.

  • Air Refueling Market Size Will Reach to USD 950 Million by 2026: Global Report by Facts & Factors

    [195+ Pages Research Report] According to the recent research report; the global Air Refueling Market in 2019 was approximately USD 450 Million. The market is expected to surge at a CAGR of 11.2% and is anticipated to surpass USD 950 Million by 2026. Top market players in the market are Cobham plc, Eaton Corporation, Lockheed Martin, Airbus, Omega Aerial Refueling Services, lnc., Boeing, Dassault Aviation, GE Aviation, Marshall Aerospace and others.New York, NY, April 20, 2021 (GLOBE NEWSWIRE) -- Facts and Factors have published a new research report titled “Air Refueling Market By System (Autonomous, Boom Refueling, and Probe & Drogue), By Activities (Water-based Activities, Land-based Activities, and Air-based Activities), By Type of Traveler (Solo, Couple, Friends/Group, and Family), and Sales Channel (Direct and Travel Agents): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026”. “According to the research report, the global Air Refueling Market was estimated at USD 450 Million in 2019 and is expected to reach USD 950 Million by 2026. The global Air Refueling Market is expected to grow at a compound annual growth rate (CAGR) of 11.2% from 2019 to 2026”. Air Refueling Market: Key Market Insights Overview The air refueling processes are carried out using two primary methodologies: flying boom and progue-and-drogue. The former is significantly faster than the latter, but it necessitates the installation of a special type of boom operator station. The method of sending aviation fuel from one aircraft to another when both are in flight modes is known as air refueling. The aircraft that transports the fuel is known as a tanker, while the aircraft that receives the fuel is known as a receiver. Air refueling is critical, particularly for military aircraft, because the additional fuel obtained allows aircraft to stay in the air for longer periods. The range of the aircraft, as well as its operational capability, can be greatly increased in this manner. Any military aircraft may be able to compensate by burning less fuel when taking off. By lowering the overall takeoff weight, this could be achieved to compensate for the heavyweight of guns, armor, and other similar items. The same aircraft will obtain additional fuel after it has taken to the air, preventing the use of excess fuel during liftoff and thereby conserving it. An effective take-off roll is also possible for aircraft that start with a small amount of fuel and then receive an additional dose once in the air. An aircraft may obtain a significant boost when taking off in this manner, allowing it to reach a significant height in a short amount of time. According to reports, air refueling can save at least 35-40 percent on fuel, particularly for flights with long routes. Request Your Free Sample Report of Air Refueling Market @ https://www.fnfresearch.com/sample/air-refueling-market (The free sample of this report is readily available on request). Our Free Sample Report Includes: 2020 Updated Report Introduction, Overview, and In-depth industry analysisCOVID-19 Pandemic Outbreak Impact Analysis Included195+ Pages Research Report (Inclusion of Updated Research)Provide Chapter-wise guidance on Request2020 Updated Regional Analysis with Graphical Representation of Size, Share & TrendsIncludes Updated List of table & figuresUpdated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue AnalysisFacts and Factors research methodology (Note: The sample of this report is updated with COVID-19 impact analysis before delivery) Key Questions Answered in this Report 1) What were the pre and post-business impacts of COVID-19 on the Air Refueling Market? 2) What is the market size, share of the Air Refueling Market? 3) Who are the top market players in Air Refueling Market? 4) What will be the future market of the Air Refueling Market? Key Offerings: Market Size & Forecast by Revenue | 2020−2026Market Dynamics – Leading trends, growth drivers, restraints, and investment opportunitiesMarket Segmentation – A detailed analysis by product, by types, end-user, applications, segments, and geographyCompetitive Landscape – Top key vendors and other prominent vendors Inquire more about this report before purchase @ https://www.fnfresearch.com/inquiry/air-refueling-market (You may enquire a report quote OR available discount offers to our sales team before purchase.) Air Refueling Market: Industry Major Market Players Cobham plcEaton CorporationLockheed MartinAirbusOmega Aerial Refueling Services lnc.BoeingDassault AviationGE AviationMarshall AerospaceParker Hannifin CorporationIsrael Aerospace Industries Ltd.Zodiac Aerospace To know an additional revised 2020 list of market players, request a sample report: https://www.fnfresearch.com/sample/air-refueling-market The Indian Parliament approved the purchase of 73 Light Combat Aircraft (Tejas Mk-1A) fighter planes and ten Light Combat Aircraft (Tejas Mk-1) trainer planes in January 2021. The majority of countries are concentrating on improving their military capabilities. Specific key reasons promising military forces to strengthen their capabilities include geopolitical challenges, territorial and border conflicts, and the need to replace aging fleets with new fourth- and fifth-generation fighter aircraft with increased payload capability and flying range. As part of the next big milestone in the Joint Strike Fighter Program, F-35A aircraft were inducted into BAE Systems Australia's (BAESA) maintenance depot in February 2021, and 12 countries have devoted themselves to ordering F-35 aircraft either as official partner nations or through foreign military sales. In January 2021, the Greek government approved the purchase of 18 Dassault Rafale jets from France for USD 3.04 billion. Therefore, an increase in spending by the military on air refueling is estimated to surge the market growth. Directly Purchase a copy of report with TOC @ https://www.fnfresearch.com/buynow/su/air-refueling-market Automated Air Refueling (A3R) is still a technology in its infancy, and numerous developments are underway to bring it to market. However, in order for A3R to become a reality, more advanced control systems, such as relative positioning systems, data link systems, and remote aerial vehicle operators, must be created. Autonomous refueling aims to seamlessly combine manned and unmanned operations. As a result, A3R will be designed to use existing structured voice command and control (C2) messages and procedures, which will be converted into data link messages that can be processed by the UAV's computer. During the forecast era, an increase in demand for air refueling systems is anticipated in North America due to a growing number of military aircraft modernization projects, ongoing research and development of advanced military aircraft platforms, and the involvement of major systems and component manufacturers. Since the military aviation market in North America is rapidly expanding, there is a high demand for air refueling systems. One of the main factors expected to improve the air refueling market in North America is the involvement of major players, OEMs, and component manufacturers. The development of the North American air refueling market is projected to be led by the United States. In terms of research and growth, launch, and the participation of key market players, North America is one of the leading markets for air refueling systems. The United States and Canada are the two largest countries in this area. North America's air refueling industry is dominated by the United States. Browse the full “Air Refueling Market By System (Autonomous, Boom Refueling, and Probe & Drogue), By Activities (Water-based Activities, Land-based Activities, and Air-based Activities), By Type of Traveler (Solo, Couple, Friends/Group, and Family), and Sales Channel (Direct and Travel Agents): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026” report at https://www.fnfresearch.com/air-refueling-market This report segments the air refueling market as follows: Global Air Refueling Market: By System Segmentation Analysis: AutonomousBoom RefuelingProbe & Drogue Global Air Refueling Market: By Component Segmentation Analysis PumpsBoomValvesProbesHosesPods Global Air Refueling Market: By Fuel Tanks Segmentation Analysis Aircraft TypeRotaryFixed Global Air Refueling Market: By Type Segmentation Analysis UnmannedManned Global Air Refueling Market: By End User Segmentation Analysis OEMAftermarket KEY REPORT POINTERS & HIGHLIGHTS: Statistically Validated Analysis of Historical, Current, and Projected Industry Trends with Authenticated Market Sizes Information and Data in terms of Value and Volume, wherever applicableDirect and Indirect Factors that Impacted the Industry as well Projected Rationales expected to affect the industry going forwardMicro, Meso, Macro, and In-Depth Analysis of Technically relevant and Commercially viable Segments and Sub-segments of the MarketHistorical and Projected Company / Vendor / OEM / Supplier Market Shares, Competitive Landscape, and Player Positioning DataHistorical and Current Demand (Consumption) and Supply (Production) Scenarios as well as Projected Supply-Demand Scenario AnalysisDetailed List of Key Buyers and End-Users (Consumers) analyzed as per Regions and ApplicationsValue Chain and Supply Chain Analysis along with Horizontal and Vertical Integration ScenariosManufacturing and Production Cost Structure Analysis including Labor Cost, Raw Material Expenses, and Other Manufacturing Expenses, wherever relevantOverview of Key Marketing Strategies and Key Sales Channels Adopted in the Market To Know COVID-19 Pre and Post Business Impact Analysis, Request a Free Report PDF Brochure: https://www.fnfresearch.com/sample/air-refueling-market Related Reports: Aircraft Seating Market: https://www.fnfresearch.com/aircraft-seating-market-by-aircraft-type-wide-body-821 Aircraft Braking System Market: https://www.fnfresearch.com/aircraft-braking-system-market-by-brake-type-carbon-304 Hybrid Aircrafts Market: https://www.fnfresearch.com/hybrid-aircrafts-market-by-type-dynastats-and-rotastats-220 Aircraft Fuel Tank Market: https://www.fnfresearch.com/global-aircraft-fuel-tank-market-by-type-external Aircraft Manufacturing Market: https://www.fnfresearch.com/global-aircraft-manufacturing-market-by-type-gliders-helicopters-1123 About Facts & Factors (FnF Research): Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business. Follow Us LinkedIn: https://www.linkedin.com/company/fnfresearch Follow Us Twitter: https://twitter.com/fnfresearch Contact Us: Facts & Factors USA: +1-347-989-3985 Email: sales@fnfresearch.com Web: https://www.fnfresearch.com Blog: http://fnfnewsblog.com

  • TPG Software Announces the Release of the Libor-to-SOFR Toolkit for 2021

    2021 Libor-to-SOFR Transition Toolkit (SOFR Genius) with focus on SOFR Formula Driven Rates for Banks and Credit Unions.

  • ‘All you need is the filing fee and a dream’: who are Gavin Newsom’s recall challengers?

    ‘All you need is the filing fee and a dream’: who are Gavin Newsom’s recall challengers?. The California governor is facing a motley mix of political opponents, from Caitlyn Jenner to Republican John Cox, a businessman who lost by 24 points

  • Oncology/Cancer Drugs Market to Reach $222.38 Bn by 2027 at 7.4% CAGR

    Increase in incidence of cancer across the globe and rise in global geriatric population, drive the growth of the global oncology/cancer Drugs market.Portland, OR, April 20, 2021 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Oncology/Cancer Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2027” According to the report, the global oncology/cancer Drugs industry generated $128.35 billion in 2019, and is expected to reach $222.38 billion by 2027, witnessing a CAGR of 7.4% from 2020 to 2027. Prime determinants of growth Increase in incidence of cancer across the globe, rise in global geriatric population, and surge in government expenditure on healthcare drive the growth of the global oncology/cancer drugs market. However, adverse effect associated with the use of cancer drugs hinder the market growth. Contrarily, high growth potential in untapped emerging economies and increase in number of pipeline drugs present new opportunities in the coming years. Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/121 Covid-19 Scenario: The outbreak of Coronavirus disease (COVID-19) has significantly impacted the oncology/cancer drugs market, as the supply chains were disrupted due to restrictions on trade of pharmaceutical ingredients and products across several countries.In addition, COVID 19 has disrupted the most crucial areas of the oncology/cancer drugs market by distorting clinical trials and drug supply chains. COVID-19’s interference with the research and development of new treatments is one of the most significant blows to the cancer drugs market. The targeted therapy segment to continue its leadership status during the forecast period Based on drug class, the targeted therapy segment held the highest share in 2019, accounting for nearly three-fifths of the global oncology/cancer drugs market, and is projected to continue its leadership status during the forecast period. This is attributed to the identification of molecular targets of cancer cells, fewer adverse effects, and availability of number of targeted therapeutics. On the other hand, the immunotherapy segment is estimated to portray the highest CAGR of 9.9% from 2020 to 2027. The breast cancer segment offers lucrative opportunities Based on indication, the breast cancer segment accounted for the largest market share in 2019, contributing to nearly one-fourth of the global oncology/cancer drugs market, and is expected to maintain its lead position during the forecast period. On the other hand, the lung cancer segment is projected to register the highest CAGR of 9.6% from 2020 to 2027. This is owing to higher incidence, increase in geriatric population, changes in lifestyle of people, and rise in smoking of tobacco which includes passive smoking, which may lead to lung cancer. North America to maintain its dominance in terms of revenue by 2027 Based on region, North America contributed to the highest share in 2019, holding nearly half of the global oncology/cancer drugs market, and is estimated to maintain its dominance in terms of revenue by 2027. However, the Asia-Pacific region is expected to witness the fastest CAGR of 9.4% from 2020 to 2027. This is due owing to increase in number of cancer affected population and rise in awareness related to different cancers. For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/121 Leading market players AbbVie Inc. AmgenAstellas Pharma Inc.AstraZeneca PLCBristol-Myers Squibb CompanyF. Hoffmann-La Roche Ltd.Johnson & Johnson (Janssen Global Services, LLC,)Merck & Co., Inc.Novartis AG, and Pfizer Inc. Avenue Basic Plan | Library Access | 1 Year Subscription | Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan. Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter Get more information: https://www.alliedmarketresearch.com/library-access We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market. Other Trending Reports: Immuno-oncology Assay Market -Global Opportunity Analysis and Industry Forecast, 2019–2026 China Oncology Drugs Market - Opportunity Analysis and Industry Forecast, 2019-2026 Digital PCR Market :Opportunity Analysis and Industry Forecast, 2020–2027 Brain Monitoring Market -Global Opportunity Analysis and Industry Forecast, 2018-2025 Ultra-Large Volume Wearable Injectors Market : Global Opportunity Analysis and Industry Forecast, 2019–2026 Diphtheria, Pertussis, and Tetanus (DTP) Vaccine Market-Global Opportunity Analysis and Industry Forecast, 2020–2027 Blood Bank Market - Global Opportunity Analysis and Industry Forecast, 2020–2027 Healthcare IT Market - U.S. Opportunity Analysis and Industry Forecast, 2017 - 2025 About Us Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. CONTACT: Contact: David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1(855)550-5975 help@alliedmarketresearch.com Web: https://www.alliedmarketresearch.com Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research